MCID: ORL015
MIFTS: 44

Oral Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases, Skin diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

MalaCards integrated aliases for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 75 53 15 17
Squamous Cell Carcinoma of Mouth 72
Mouth Squamous Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050866
UMLS 72 C0585362

Summaries for Oral Squamous Cell Carcinoma

Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and tongue squamous cell carcinoma. An important gene associated with Oral Squamous Cell Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Raspberry and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, tongue and bone.

Wikipedia : 75 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 318)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.7 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
2 tongue squamous cell carcinoma 32.2 UCA1 MIR21 MALAT1
3 glioblastoma 31.8 TUG1 MIR21 MIR137 MALAT1 HOTAIR H19
4 melanoma 31.6 UCA1 MIR193A MIR137 MIR100 MALAT1 HOTAIR
5 esophageal cancer 31.6 UCA1 MIR21 MALAT1 HOTAIR H19 CCAT1
6 bladder cancer 31.5 UCA1 TUG1 MIR21 MIR100 MALAT1 HOTAIR
7 lung cancer susceptibility 3 31.5 TUG1 MALAT1 HOTAIR H19 CCAT1
8 pancreatic ductal adenocarcinoma 31.4 UCA1 MIR21 MALAT1 HOTAIR H19
9 cervical cancer 31.3 UCA1 TUG1 NEAT1 MIR21 MALAT1 HOTAIR
10 hepatocellular carcinoma 31.3 UCA1 TUG1 NEAT1 MIR21 MIR137 MALAT1
11 colorectal cancer 31.2 UCA1 TUG1 SOX21-AS1 NEAT1 MIR21 MIR137
12 nasopharyngeal carcinoma 31.2 NEAT1 MIR100 MALAT1 HOTAIR H19 FOXCUT
13 kidney cancer 31.1 MIR21 MALAT1 HOTAIR H19
14 ovarian cancer 31.1 UCA1 TUG1 NEAT1 MIR21 MIR100 MALAT1
15 osteogenic sarcoma 31.1 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19
16 pancreatic cancer 31.1 UCA1 TUG1 NEAT1 MIR21 MIR100 MALAT1
17 prostate cancer 31.1 UCA1 TUG1 NEAT1 MIR21 MIR100 MALAT1
18 gallbladder cancer 31.0 UCA1 TUG1 MALAT1 HOTAIR H19 CCAT1
19 laryngeal squamous cell carcinoma 31.0 NEAT1 MIR21 MALAT1 HOTAIR H19 CCAT1
20 pre-eclampsia 31.0 TUG1 MALAT1 HOTAIR H19
21 myeloma, multiple 31.0 UCA1 TUG1 MALAT1 HOTAIR H19 CCAT1
22 leukemia, acute myeloid 31.0 UCA1 TUG1 MIR21 MALAT1 HOTAIR CCAT1
23 gastric cancer 30.9 UCA1 TUG1 NEAT1 MIR21 MALAT1 LINC00668
24 breast cancer 30.9 UCA1 TUG1 NEAT1 MIR21 MALAT1 HOTAIR
25 glioma 30.9 UCA1 NEAT1 MIR21 MALAT1 HOTAIR H19
26 endometrial cancer 30.9 UCA1 TUG1 NEAT1 HOTAIR H19 CCAT1
27 lung cancer 30.8 UCA1 TUG1 NEAT1 MIR21 MIR137 MIR100
28 lung squamous cell carcinoma 30.5 TUG1 CCAT2 CCAT1
29 oral cancer 11.4
30 leukoplakia 11.0
31 ovarian epithelial cancer 10.9 MALAT1 HOTAIR H19
32 triple-receptor negative breast cancer 10.9 MALAT1 HOTAIR
33 oral leukoplakia 10.9
34 pituitary adenoma 10.9 MALAT1 HOTAIR H19 CCAT2
35 small cell cancer of the lung 10.9 TUG1 MIR21 MALAT1 HOTAIR CCAT2
36 thyroid cancer, nonmedullary, 1 10.9 NEAT1 MALAT1 HOTAIR H19
37 malignant glioma 10.8 TUG1 NEAT1 HOTAIR CCAT1
38 clear cell renal cell carcinoma 10.8 TUG1 MIR21 MALAT1 CCAT2
39 cholangiocarcinoma 10.8 UCA1 TUG1 NEAT1 MIR21 MALAT1 H19
40 gastrointestinal system cancer 10.8 MALAT1 HOTAIR H19
41 gastric cardia adenocarcinoma 10.8 HOTAIR H19
42 obsolete: squamous cell carcinoma of head and neck 10.8
43 lichen planus 10.8
44 renal cell carcinoma, nonpapillary 10.8 UCA1 TUG1 MALAT1 HOTAIR H19 CCAT1
45 intrahepatic cholangiocarcinoma 10.8 TUG1 CCAT2 CCAT1
46 oral lichen planus 10.8
47 ovarian serous carcinoma 10.7 MIR21 MIR100
48 oral submucous fibrosis 10.7
49 papilloma 10.7
50 adamantinoma of long bones 10.7 UCA1 TUG1 NEAT1 MALAT1 HOTAIR H19

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Raspberry Approved Phase 1, Phase 2
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
4
Mecasermin Approved, Investigational Phase 1, Phase 2 68562-41-4
5
Morphine Approved, Investigational Phase 1, Phase 2 57-27-2 5288826
6
Dasatinib Approved, Investigational Phase 1, Phase 2 302962-49-8 3062316
7
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
Fluorouracil Approved Phase 2 51-21-8 3385
10
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 1406-16-2
12
Calcium Approved, Nutraceutical Phase 1, Phase 2 7440-70-2 271
13
Calcitriol Approved, Nutraceutical Phase 1, Phase 2 32222-06-3 5280453 134070
14 Omega 3 Fatty Acid Phase 2
15 arginine Phase 2
16 Antineoplastic Agents, Phytogenic Phase 2
17 Albumin-Bound Paclitaxel Phase 2
18 Antioxidants Phase 2
19 Protective Agents Phase 2
20 Micronutrients Phase 1, Phase 2
21 Hormones Phase 1, Phase 2
22 Trace Elements Phase 1, Phase 2
23 Dihydroxycholecalciferols Phase 1, Phase 2
24 Vitamins Phase 1, Phase 2
25 Nutrients Phase 1, Phase 2
26 Vasoconstrictor Agents Phase 1, Phase 2
27 Calciferol Phase 1, Phase 2
28 Calcium, Dietary Phase 1, Phase 2
29 Bone Density Conservation Agents Phase 1, Phase 2
30 Antibodies Phase 1, Phase 2
31 Antibodies, Monoclonal Phase 1, Phase 2
32 Immunoglobulins Phase 1, Phase 2
33 Pharmaceutical Solutions Phase 1, Phase 2
34 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
35 insulin Phase 1, Phase 2
36 Insulin, Globin Zinc Phase 1, Phase 2
37 Analgesics Phase 2
38 Cyclooxygenase Inhibitors Phase 2
39 Analgesics, Non-Narcotic Phase 2
40 Peripheral Nervous System Agents Phase 2
41 Cyclooxygenase 2 Inhibitors Phase 2
42 Anti-Inflammatory Agents, Non-Steroidal Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Antirheumatic Agents Phase 2
45 Mitogens Phase 2
46 Protein Kinase Inhibitors Phase 2
47
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
48 Tubulin Modulators Phase 2
49 Immunosuppressive Agents Phase 2
50 Antimitotic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
2 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
3 Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma Completed NCT01542931 Phase 2, Phase 3 TPF induction chemotherapy
4 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
5 A Double Blind, Randomised, Placebo Controlled, Feasibility Phase III Clinical Trial of Peri-operative Immune-enhancing Feed in Patients Undergoing Surgery for Advanced Head and Neck Cancer Completed NCT01314755 Phase 2
6 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
7 Treatment of Oral Lichen Planus Lesions Completed NCT00746772 Phase 2 Purslane 235mg/day in one dosage;Placebo : one dosage
8 Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity Completed NCT00953849 Phase 1, Phase 2 Celecoxib;Calcitriol;Celecoxib plus Calcitriol
9 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
10 Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma Recruiting NCT03502148 Phase 1, Phase 2 PRV111 (Cisplatin Transmucosal System)
11 A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas Recruiting NCT03085147 Phase 1, Phase 2 Olaparib
12 Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial Recruiting NCT02290145 Phase 2 TPF group
13 GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial Recruiting NCT02285530 Phase 2 TPF induction chemotherapy
14 A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma Recruiting NCT03041701 Phase 1, Phase 2 Dasatinib;Ganitumab
15 Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck Active, not recruiting NCT01414426 Phase 2 vandetanib
16 A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma Active, not recruiting NCT02285543 Phase 2 TPF induction chemotherapy
17 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
18 A Randomized Phase II Trial of Low Stathmin Expression as a Predictive Biomarker for OSCC Patients Receiving TPF Induction Chemotherapy Followed by Radical Surgery and Radiotherapy/Chemoradiotherapy Not yet recruiting NCT03326947 Phase 2 docetaxel, cisplatin and 5-fluorouracil
19 Free Soft Tissue Graft in Treatment of Oral Lichen Planus Unknown status NCT00737854 Phase 1
20 Phase I Trial Of Intratumoral EGFR Antisense DNA And DC-Chol Liposomes In Advanced Oral Squamous Cell Carcinoma Completed NCT00009841 Phase 1 DC-cholesterol liposome
21 The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Unknown status NCT02009852
22 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study) Unknown status NCT03109457
23 Pivotal Validation Study of Salivary Biomarkers for the Risk Stratification of Patients With Lesions Suspicious for Oral Squamous Cell Carcinoma Unknown status NCT01587573
24 Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma Unknown status NCT01987934
25 The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma Unknown status NCT01946230
26 SEND Trial The Role of Selective Neck Dissection Used Electively in Patients With Early Oral Squamous Cell Carcinoma (1-3cm Primary Size) and No Clinical Evidence of Lymph Node Metastases in the Neck Unknown status NCT00571883
27 Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus. Diagnostic Value of White Light Endoscopy, Narrow Band Imaging and Chromoendoscopy for Detection of Esophageal Manifestation in Patients With Oral Lichen. Unknown status NCT02532166
28 The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Unknown status NCT00173849
29 The Relation of Microtubule-Associated Protein 2 and Cell Migration Unknown status NCT00174109
30 The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer Unknown status NCT01627119
31 A Phase 1b Pilot Study Evaluating Oral Administration of Freeze-Dried Black Raspberries in Pre-Surgical Patients With Oral Squamous Cell Carcinoma Completed NCT01465776
32 Epstein-Barr Detection in Squamous Cell Carcinoma and Healthy Oral Mucosa Completed NCT01039272
33 Fluorescent Visualization in Early Oral Cancer Completed NCT02306967
34 Molecular Mechanisms of Precancerous and Cancerous Lesions of the Oral Cavity Completed NCT03026361
35 Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma. Completed NCT02323672
36 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
37 A Cohort Study on Prediction of Malignant Transformation of Oral Epithelial Dysplasia by p16 Methylation Completed NCT00835341
38 Detection of Salivary 8-Hydroxy-2-Deoxyguanosine and Total Antioxidant Capacity in Patients With Oral Premalignant and Malignant Lesions Completed NCT03830710
39 Assessing Efficacy of Neoadjuvant Chemoradiotherapy as a Treatment Plan for Patients With Stage IVa Oral Cancer. Completed NCT03923998 Early Phase 1 Neoadjuvant chemotherapy
40 Interest of Oral Tissue Autofluorescence for the Screening of Precancerous Lesions and Cancer in Population With Tobacco and Alcohol Abuse. Completed NCT01167790
41 Comparison of Detection of Human Papillomavirus on Tissue, Saliva and Serum Completed NCT01043328
42 Real-time Semi-quantification of Endoscopic Ultrasound Elastography and Contrast-enhancement Using Strain Histograms (SH) and Contrast-enhancement (CE) for the Differentiation of Focal Pancreatic Masses and the Assessment of Lymph Node Involvement Completed NCT02459041
43 A Randomized,Multicenter,Prospectie,Controlled Clinical Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma. Recruiting NCT02743832
44 Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma Recruiting NCT03554967
45 Survival Benefit of Elective Neck Dissection for Patients With T1,2N0M0 Oral Squamous Cell Carcinoma—A Prospective Multicenter Randomized Controlled Study Recruiting NCT01334320
46 Multispectral Optoacoustic Imaging Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases: a Single Center Proof of Concept Study Recruiting NCT03923881
47 Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma Recruiting NCT03877159
48 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
49 The Role of the Central Memory Phenotype in Predicting Response to PD-1 Inhibition in Pre-clinical Models of Oral Cancer Recruiting NCT03862066
50 Adjuvant Radiotherapy in Early Stage Oral Cancers (AREST) Recruiting NCT03853655

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

Anatomical Context for Oral Squamous Cell Carcinoma

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

41
Lymph Node, Tongue, Bone, Endothelial, T Cells, Skin, Neutrophil

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 8673)
# Title Authors PMID Year
1
Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. 38 88
19396866 2009
2
The expression profile of microRNAs in a model of 7,12-dimethyl-benz[a]anthrance-induced oral carcinogenesis in Syrian hamster. 38 88
19435529 2009
3
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. 38 88
18381414 2008
4
Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. 88
18946016 2008
5
Co-SLD suppressed the growth of oral squamous cell carcinoma via disrupting mitochondrial function. 38
31062618 2019
6
MiR-638 suppresses the progression of oral squamous cell carcinoma through wnt/β-catenin pathway by targeting phospholipase D1. 38
31379206 2019
7
MiR-29a inhibits the progression of oral squamous cell carcinoma by targeting Wnt/β-catenin signalling pathway. 38
31342798 2019
8
Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma. 38
30831033 2019
9
Long noncoding RNA TUG1 regulates the development of oral squamous cell carcinoma through sponging miR-524-5p to mediate DLX1 expression as a competitive endogenous RNA. 38
30980391 2019
10
Circle RNA hsa_circRNA_100290 serves as a ceRNA for miR-378a to regulate oral squamous cell carcinoma cells growth via Glucose transporter-1 (GLUT1) and glycolysis. 38
31187488 2019
11
Esophageal cancer related gene-4 inhibits the migration and proliferation of oral squamous cell carcinoma through BC200 lncRNA/MMP-9 and -13 signaling pathway. 38
31152845 2019
12
Leptin -2548 G/A polymorphisms are associated to clinical progression of oral cancer and sensitive to oral tumorization in nonsmoking population. 38
31021458 2019
13
Myiasis in patients with oral squamous cell carcinoma-a systematic review and protocol for management. 38
31119420 2019
14
Exome sequencing of oral leukoplakia and oral squamous cell carcinoma implicates DNA damage repair gene defects in malignant transformation. 38
31422212 2019
15
Upregulated LOX and increased collagen content associated with aggressive clinicopathological features and unfavorable outcome in oral squamous cell carcinoma. 38
31140650 2019
16
Identification of salivary metabolites for oral squamous cell carcinoma and oral epithelial dysplasia screening from persistent suspicious oral mucosal lesions. 38
30539290 2019
17
The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis. 38
31093793 2019
18
Computational models for predicting anticancer drug efficacy: A multi linear regression analysis based on molecular, cellular and clinical data of oral squamous cell carcinoma cohort. 38
31416538 2019
19
Addition of tumour infiltration depth and extranodal extension improves the prognostic value of the pathological TNM classification for early-stage oral squamous cell carcinoma. 38
31021008 2019
20
Health-related quality of life in patients with T1N0 oral squamous cell carcinoma: selective neck dissection compared with wait and watch surveillance. 38
31230853 2019
21
The significance of tumor budding in oral cancer survival and its relevance to the eighth edition of the American Joint Committee on Cancer staging system. 38
31012518 2019
22
Ursolic acid induces apoptosis and autophagy in oral cancer cells. 38
31062913 2019
23
Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders. 38
31422202 2019
24
Shear wave elastography in differentiating between benign and malignant cervical lymph nodes in patients with oral carcinoma. 38
30894023 2019
25
QKI, a miR-200 target gene, suppresses epithelial-to-mesenchymal transition and tumor growth. 38
31026342 2019
26
18F-FDG and 18F-FAMT PET-derived metabolic parameters predict outcome of oral squamous cell carcinoma. 38
30778900 2019
27
Construction of prognostic risk prediction model of oral squamous cell carcinoma based on co-methylated genes. 38
31198983 2019
28
miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5. 38
31322243 2019
29
LncRNA PAPAS promotes oral squamous cell carcinoma by upregulating transforming growth factor-β1. 38
31099126 2019
30
Treatment for oral squamous cell carcinoma: Impact of surgeon volume on survival. 38
31422214 2019
31
CDK4, CDK6, cyclin D1 and Notch1 immunocytochemical expression of oral brush liquid-based cytology for the diagnosis of oral leukoplakia and oral cancer. 38
31172614 2019
32
Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer. 38
31400079 2019
33
The effects of the tobacco carcinogens N`-nitrosonornicotine and dibenzo[a,l]pyrene individually and in combination on DNA damage in human oral leukoplakia and on mutagenicity, and mutation profiles in lacI mouse tongue. 38
31433626 2019
34
Cisplatin-Resistance in Oral Squamous Cell Carcinoma: Regulation by Tumor Cell-Derived Extracellular Vesicles. 38
31416147 2019
35
The Oral Mouse Microbiome Promotes Tumorigenesis in Oral Squamous Cell Carcinoma. 38
31387932 2019
36
Identification of AUNIP as a candidate diagnostic and prognostic biomarker for oral squamous cell carcinoma. 38
31409573 2019
37
Clinical significance of the G8 screening tool in elderly patients with oral squamous cell carcinoma. 38
31410674 2019
38
Prognostic and predictive markers for perineural and bone invasion of oral squamous cell carcinoma. 38
31435075 2019
39
Is Toombak a risk factor for oral leukoplakia and oral squamous cell carcinoma ? A systematic review. 38
31436350 2019
40
Alpinetin Inhibits Oral Squamous Cell Carcinoma Proliferation via miR-211-5p Upregulation and Notch Pathway Deactivation. 38
31403340 2019
41
Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC). 38
31405379 2019
42
Tunicamycin-induced endoplasmic reticulum stress up-regulates tumour-promoting cytokines in oral squamous cell carcinoma. 38
31071674 2019
43
CXCL12 is associated with FoxP3+ tumor-infiltrating lymphocytes and affects the survival of patients with oral squamous cell carcinoma. 38
31423170 2019
44
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma. 38
31434965 2019
45
IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells. 38
30949979 2019
46
Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a. 38
31378890 2019
47
The Importance of Inducible Nitric Oxide Synthase and Nitrotyrosine as Prognostic Markers for Oral Squamous Cell Carcinoma. 38
31379002 2019
48
Systematic review confirms that lymph node compromise is associated with the prognosis of oral squamous cell carcinoma. 38
31151657 2019
49
MicroRNA-140-5p inhibits the tumorigenesis of oral squamous cell carcinoma by targeting p21-activated kinase 4. 38
31393040 2019
50
KLF4 expression in the surgical cut margin is associated with disease relapse of oral squamous cell carcinoma. 38
31078500 2019

Variations for Oral Squamous Cell Carcinoma

Cosmic variations for Oral Squamous Cell Carcinoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM563 NRAS upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.34G>A p.G12S 1:114716127-114716127 0

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification EMS1 Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification TAOS1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification ORAOV1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Oral Squamous Cell Carcinoma

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of angiogenesis GO:0016525 9.33 MIR21 MIR193A MIR137
2 negative regulation of blood vessel endothelial cell migration GO:0043537 9.32 MIR193A MIR137
3 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.26 MIR21 MIR137
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.13 MIR21 MIR193A MIR137
5 gene silencing by miRNA GO:0035195 9.1 NEAT1 MIR21 MIR193A MIR137 MIR100 H19

Sources for Oral Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....